LogicBio Therapeutics

Fred Chereau, CEO

Oct. 13 | 4:00pm | BlueRock Therapeutics Ballroom

Lexington, MA

(NASDAQ: LOGC)

In-person Presentation

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company’s first platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell’s natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company’s second platform, sAAVy™, is an adeno-associated virus capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. 

www.logicbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions